This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here
In: Sin categoría
Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers
08/01/2024Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an…
Read More
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers
21/09/2023September 21, 2023 Debiopharm to boost its ADC oncology pipeline through multi-asset partnership with SunRock’s antibody portfolio integrating Multilink™ & AbYlink™…
Read More
Research activity starts in Santiago at the Sionlla Biopolo with the installation of SunRock and Zinpro
08/05/2023The company from Santiago de Compostela is searching for antibodies against cancer, while the multinational is working on animal welfare. The…
Read More
SunRock Biopharma and VHIO are beneficiaries of a project funded with 1.7 million euros for the development of new antibodies for the treatment of solid tumors
24/03/2023The initiative aims to advance the development of new therapeutic options for breast cancer, colorectal cancer, and head and neck cancer….
Read More
SunRock Biopharma and IDIS secure 1.8 million euros in funding for the IMPANC project.
27/02/2023This initiative aims to advance the study of a new and effective therapeutic alternative that improves the lives of pancreatic cancer…
Read More
SunRock Biopharma receives the Bioga Award as a Competitive BioCompany
20/01/2023The company’s experience and trajectory in the development of cancer treatments have made SunRock worthy of this recognition. The Business Technology…
Read More
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein
21/09/2022Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours LONDON and SANTIAGO DE COMPOSTELA, Spain,…
Read More
